Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter
Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 sales growth and near-term profitability based on raised full-year net sales guidance, Q3 adjusted EBITDA outperformance, and Q4 adjusted EBITDA guidance that points to slower margin expansion.
Market read
Q3 beats plus raised full-year sales guidance are supportive, but Q4 EBITDA guidance and margin headwinds (FX, input costs, mix) add near-term caution.
What to watch
FX was a larger headwind than assumed in guidance (160 bps vs 100 bps), and gross margin declined due to mix and cost pressures, which may reappear if FX or input costs worsen.
Background
Herbalife held its Q3 2026 earnings call (release date Nov 2, 2026) and discussed performance drivers, regional trends, and a new modular customer engagement platform.
Ticker impact
Herbalife reported Q3 net sales of $1.4B (+6% YoY) and raised full-year net sales guidance, while guiding Q4 adjusted EBITDA to $145-$165M.
Likely upward bias as traders price in raised full-year guidance and Q3 outperformance, tempered by concerns about Q4 margin and FX-driven earnings pressure.
The article contains specific Q3 beats (net sales and adjusted EBITDA), explicit full-year guidance increases, and a concrete Q4 adjusted EBITDA range that signals lower margin versus Q3.
Market effects
GLP-1-driven demand framing and nutrition club productivity could influence sentiment toward nutrition and direct-selling peers, but the article is company-specific.
India strength and Asia Pacific growth are highlighted, while EMEA and China declines may keep regional risk premia elevated for similar consumer-nutrition distributors.
Limited broader macro spillover; the main cross-market signal is FX sensitivity and margin trajectory guidance.
Counterpoint
Despite raised full-year sales guidance, the Q4 adjusted EBITDA range implies margin compression and management flagged ongoing input-cost monitoring, which could cap upside.
Key entities
- companyHerbalife Ltd
Reported Q3 2026 results, raised full-year net sales guidance, and provided Q4 adjusted EBITDA guidance; discussed nutrition club productivity and a modular customer engagement platform.
- executiveJohn DeSimone
Interim CEO who outlined product repositioning for GLP-1 users and plans for Bionic, Life.io integration, and the Protocol platform.
- executiveScott Schaefer
CFO who detailed Q3 outperformance drivers, regional performance, gross margin bridge, and guidance.
